Generic

Escitalopram Oxalate.

Indications

Escitalopram Oxalate is indicated in the-

• Treatment of major depressive episodes.
• Treatment of panic disorder with or without agoraphobia.
• Treatment of social anxiety disorder (social phobia).
• Treatment of generalized anxiety disorder.
• Treatment of obsessive-compulsive disorder.

Pharmacology

Escitalopram is an orally managed specific serotonin reuptake inhibitor (SSRI). Escitalopram is the immaculate S-enantiomer of the racemic bicyclic phthalate subordinate citalopram. Escitalopram is at the slightest 100 overlaps more powerful than the R-enantiomer with regard to restraint of 5-HT reuptake. Escitalopram has no or exceptionally moo partiality for serotonergic or other receptors counting alpha- and beta-adrenergic Dopamine, Histamine, Muscarinic, and benzodiazepine receptors.

Dosage & Administration

Safety of daily doses above 20 mg has not been demonstrated. Escitalopram Oxalate is administered as a single daily dose and may be taken with or without food.

Major depressive episodes: Usual dosage is 10 mg once daily. Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily. Usually, 2-4 weeks are necessary to obtain an antidepressant response. After the symptoms resolve, treatment for at least 6 months is required for consolidation of the response.

Panic disorder with or without agoraphobia: An initial dose of 5 mg is recommended for the first week before increasing the dose to 10 mg daily. The dose may be further increased, up to a maximum of 20 mg daily, dependent on individual patient response. Maximum effectiveness is reached after about 3 months. The treatment lasts several months.

Social anxiety disorder: Usual dosage is 10 mg once daily. Usually, 2-4 weeks are necessary to obtain symptom relief. The dose may subsequently, depending on individual patient response, be decreased to 5 mg or increased to a maximum of 20 mg daily. Social anxiety disorder is a disease with a chronic course, and treatment for 12 weeks is recommended to consolidate response. Long-term treatment of responders has been studied for 6 months and can be considered on an individual basis to prevent relapse; treatment benefits should be re-evaluated at regular intervals. Social anxiety disorder is a well-defined diagnostic terminology of a specific disorder, which should not be confounded with excessive shyness. Pharmacotherapy is only indicated if the disorder interferes significantly with professional and social activities. The place of this treatment compared to cognitive behavioural therapy has not been assessed. Pharmacotherapy is part of an overall therapeutic strategy.

Generalised anxiety disorder: Initial dosage is 10 mg once daily. Depending on the individual patient response, the dose may be increased to a maximum of 20 mg daily. Long term treatment of responders has been studied for at least 6 months in patients receiving 20 mg/day. Treatment benefits and dose should be re-evaluated at regular intervals.

Obsessive-Compulsive Disorder: Initial dosage is 10 mg once daily. Depending on the individual patient response, the dose may be increased to a maximum of 20 mg daily. As OCD is a chronic disease, patients should be treated for a sufficient period to ensure that they are symptom-free. Treatment benefits and dose should be re-evaluated at regular intervals.

Interaction

Antidepressants such as SSRIs and related antidepressants should not be begun for at least two weeks after quitting an MAOI. An MAOI, on the other hand, should not be taken until at least one week after an SSRI or similar antidepressant has been discontinued (2 weeks in the case of paroxetine and sertraline, at least 5 weeks in the case of fluoxetine).

Contraindications

Escitalopram is contraindicated in patients with known extreme touchiness to Escitalopram or Citalopram or any of the dormant fixings of the medicate item. Concomitant utilize of escitalopram in patients taking monoamine oxidase/pimozide is contraindicated.

Side Effects

SSRIs are less calming and have less antimuscarinic and cardiotoxic impacts than tricyclic antidepressants. Side-effects of the SSRIs incorporate gastrointestinal impacts (dose-related and reasonably common incorporate queasiness, heaving, dyspepsia, stomach torment, the runs, stoppage), anorexia with weight misfortune (expanded craving and weight pick up moreover detailed), and extreme touchiness responses counting hasty, urticaria, angioedema, anaphylaxis, arthralgia, myalgia, and photosensitivity; other side-effects incorporate dry mouth, anxiety, uneasiness, migraine, sleep deprivation, tremor, tipsiness, asthenia, mental trips, laziness, shakings, galactorrhea, sexual brokenness, urinary maintenance, sweating, hypomania or lunacy, development clutters and dyskinesias, visual unsettling influences.

Pregnancy & Lactation

When treating a pregnant lady with Escitalopram amid the third trimester, the doctor ought to carefully consider the potential dangers and benefits of treatment. It is excreted in the human breast drain. The choice of whether to proceed or suspend either nursing or Escitalopram treatment ought to take into consideration the chance of citalopram introduction for the newborn child and the benefits of Escitalopram treatment for the mother.

Precautions & Warnings

SSRIs ought to be utilized with caution in patients with epilepsy (maintain a strategic distance from in the event that ineffectively controlled, cease on the off chance that writhing’s create), concurrent electroconvulsive treatment (drawn out seizures detailed with fluoxetine), history of lunacy, cardiac infection, diabetes mellitus, angle-closure glaucoma, concomitant utilize of drugs that increment hazard of dying, history of dying disarranges (particularly gastro-intestinal dying), hepatic and renal impedance.

Therapeutic Class

SSRIs & related anti-depressant drugs.

Storage Conditions

Keep the temperature below 30°C and away from light and moisture. Keep out of children's reach.

Pharmaceutical Name

Incepta Pharmaceuticals Ltd.